Dendrimers drug carrier

A number of studies have examined the use of a dendrimer drug carrier to treat a variety of tumors. One approach has been based on the exploitation of the enhanced permeability and retention effect (EPR effect) to localize drug conjugates in tumor tissue. " A second approach has involved the conjugation of a... 

Gupta, U., et al. (2006), A review of in vitro-in vivo investigations on dendrimers The novel nanoscopic drug carriers, Nanomed. Nanotechnol. Biol. Med., 2(2), 66-73. 

Bai SH, Thomas C, Rawat A, Ahsan F. Recent progress in dendrimer-based nanocarriers. Crit. Rev. Ther. Drug Carrier Sys. 2006 23 437-495. 

Biodegradable Polymers as Drug Carriers, p. 176. Colloids and Colloid Drug Delivery System, p. 636. Dendrimers, p. 872. 

Polymers are the most common materials that are used as drug carriers due to their diverse chemistry and safety characteristics in the body [1]. A polymer can be used to carry drugs in different maimers (or forms), such as conjugates [3], dendrimers [4], nanoparticles [5], micelles [6, 7], nanogels [7], or polymer-somes [8], using a variety of delivery mechanisms. Figure 1 shows the structures of common polymer carriers. 

Fig. 1 Various polymeric drug carriers (a) conjugates, (b) dendrimers, (c) nanoparticles, (d) micelles, (e) nanogels, (f) polymersomes...

One example of a dendrimer as an anticancer drug carrier is the covalent attachment of drug molecules to the dendrimer periphery, which is in a conjugated form. The generation number of the dendrimer determines the drug... 

Dendrimer-based drug delivery systems have been successful in both improving bioavailability as well as targeting drugs. The main advantages for the use of dendrimers as drug carriers reside in their multivalent design and their well-defined structure that results from the stepwise, iterative approach used in their preparation. The anionic and neutral dendrimers have been shown to be less toxic than the cationic dendrimers but at the same time they suffer from lower permeability compared to cationic dendrimers. Typically the smaller size of dendrimers... 

C. Yiyun, X. Tongwen, Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers, Eur. J. Med. Chem. 40 (2005) 1188-1192. 

Dendrimers are small (typically less than lOnm in diameter) in comparison to other drug-delivery vehicles such as linear polymers, micelles (50-200 nm), and liposomes (100-1000nm). The small size results in rapid renal filtration and elimination via the urine compared to larger carriers. To reach an effective therapeutic concentration of the drug in the tumor tissue, a dendritic drug carrier needs to balance kidney clearance and elimination via the fiver and reticuloendothelial system (RES) against the passive accumulation resulting from the EPR effect. RES clearance is more pronoimced for... 

Figure 41 Comparison of PAMAM dendrimers as passive or covalent drug carriers with a folate receptor ligand. FA, folic acid MTX, methotrexate PBS, phosphate-buffered saline. Reproduced with permission from Patti, A. K. Kukowska-Latallo, J. F. Baker, J. R. Adv. Drug Deliv. Rev. 2005, 57, 2203. Copyright 2005 Advanced drug delivery reviews.

Washington, D.C., 2001, p.214,012 DENDRIMERS NOVEL CARRIERS FOR ORAL AND PARENTERAL DRUG DELIVERY... 

---